Elevance Health, Inc. Common Stock (ELV)

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased Elevance Health, Inc. (“Elevance” or the “Company”) (NYSE: ELV) common stock between April 18, 2024, and October 16, 2024, inclusive (the “Class Period”). Elevance investors have until July 11, 2025 to file a lead plaintiff motion.

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Elevance Health, Inc. (“Elevance” or the “Company”) (NYSE: ELV) investors concerning the Company’s possible violations of the federal securities laws.

Law Offices of Howard G. Smith announces an investigation on behalf of Elevance Health, Inc. (“Elevance” or the “Company”) (NYSE: ELV) investors concerning the Company’s possible violations of federal securities laws.

The law firm of Robbins Geller Rudman & Dowd LLP announces that the Elevance Health class action lawsuit – captioned Miller v. Elevance Health, Inc., No. 25-cv-00923 (S.D. Ind.) – seeks to represent purchasers of Elevance Health, Inc. (NYSE: ELV) common stock and charges Elevance Health and certain of Elevance Health’s top executives with violations of the Securities Exchange Act of 1934.

The Law Offices of Frank R. Cruz announces an investigation of Elevance Health, Inc. (“Elevance” or the “Company”) (NYSE: ELV) on behalf of investors concerning the Company’s possible violations of federal securities laws.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

SAN DIEGO, CA - May 13, 2025 ( NEWMEDIAWIRE ) - Robbins LLP informs stockholders that a class action was filed on behalf of all purchasers of Elevance Health, Inc. (NYSE: ELV) common stock between April 18, 2024 and October 16, 2024. Elevance is a healthcare company that, among other things, provides health insurance plans to a variety of markets.

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Elevance Health, Inc. (“Elevance” or “the Company”) (NYSE: ELV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elevance Health, Inc. (NYSE: ELV) and certain of the Company’s senior executives for potential violations of the federal securities laws.

NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Elevance Health, Inc. (“Elevance” or the “Company”) (NYSE: ELV).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of common stock of Elevance Health, Inc. (NYSE: ELV) between April 18, 2024, and October 16, 2024. Elevance describes itself as a “healthcare company that provides health insurance plans to a variety of markets.”

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Elevance Health, Inc. (“Elevance” or the “Company”) (NYSE: ELV) and reminds investors of the July 11, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Elevance Health, Inc. (NYSE: ELV) reported first quarter 2025 results.

Elevance Health (NYSE: ELV) will release first quarter 2025 financial results on April 22, 2025, at 6:00 a.m. Eastern Daylight Time (“EDT”). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers:

Elevance Health, Inc. (NYSE: ELV) reported fourth quarter and full year 2024 results.

Elevance Health (NYSE: ELV) will release fourth quarter and full year 2024 financial results on January 23, 2025, at 6:00 a.m. Eastern Standard Time (“EST”). Management will review these results and its outlook during a conference call at 8:30 a.m. EST that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers:

SAN DIEGO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Elevance Health Inc. (NASDAQ: ELV) to determine whether certain Elevance officers and directors violated securities laws and breached fiduciary duties to shareholders. Elevance is a healthcare company that supports consumers, families, and communities across the entire care journey.

AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) of “a+” (Excellent) of the core Blue Cross Blue Shield (BCBS)-branded insurance subsidiaries of Elevance Health, Inc. (Elevance) (Indianapolis, IN) [NYSE: ELV], as well as its life insurance subsidiaries. These companies collectively are referred to as Anthem Health. At the same time, AM Best has affirmed the Long-Term ICR of “bbb+” (Good), the Long- and Short-Term Issue Credit Ratings (Long-Term IR; Short-Term IR) of Elevance and the Long-Term IR on the existing surplus notes of Anthem Insurance Companies, Inc. (Indianapolis, IN).

Elevance Health (NYSE: ELV) announced today that senior management is scheduled to present at the UBS Global Healthcare Conference in Rancho Palos Verdes, California on November 12, at 7:15 a.m. Pacific Standard Time (PST) / 10:15 a.m. Eastern Standard Time (EST). All interested parties are invited to listen to a live webcast of the presentation by visiting www.elevancehealth.com and selecting the “Investors” link. You may also access the link here.

Elevance Health (NYSE: ELV) announced today the appointment of Nathan Rich as Vice President, Investor Relations, effective November 11, 2024. In this role, Mr. Rich will lead Elevance Health's investor relations efforts, providing strategic leadership to support the company’s growth initiatives and strengthen relationships within the investment community. He will also serve as a member of the company’s executive leadership team and will report directly to Mark Kaye, Executive Vice President and Chief Financial Officer. Mr. Rich succeeds Stephen Tanal, who now serves as Chief Financial Officer for Elevance Health’s Government Health Benefits business.

Elevance Health, Inc. (NYSE: ELV) reported third quarter 2024 results.

Elevance Health (NYSE: ELV) will release third quarter 2024 financial results on October 17, 2024, at 6:00 a.m. Eastern Daylight Time (“EDT”). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers:

Everybody loves finding a bargain or getting a good deal, and it's no different when it comes to stocks. The RSI indicator is a great way to find them.

Elevance Health and its philanthropic arm, Elevance Health Foundation, are committed to strengthening the health of communities across the U.S. through community resiliency and disaster response efforts related to Hurricane Helene.

The Whole Health Index (WHI), created by Elevance Health, Inc. (NYSE: ELV) physicians, data scientists, and researchers, is a first-of-its-kind assessment of health. Using a scale of 0 to 100, the WHI can evaluate a person or group’s relative health over time and assess the physical, behavioral, and social factors that influence it.